Efficacy and safety of minodronate in the treatment of postmenopausal osteoporosis with low back pain: a single-centre and randomized controlled trial

Author:

Wang Huan1,Huang Jie1,Tao Liyuan1,Liu Dongyang1,Song Chunli1ORCID

Affiliation:

1. Peking University Third Hospital

Abstract

AbstractBackground:Low back pain is one of the most common symptoms of osteoporosis (OP). The pain can seriously affect patients' mood and quality of life; it can also further aggravate bone loss, causing a serious social burden. Minodronate is a third-generation bisphosphonate. Daily oral administration of minodronate significantly reduces levels of bone resorption markers and rapidly improves symptoms of low back pain in patients with OP.Methods:This is a single-centre, randomized, open-label controlled trial with a 24-week duration. Seventy-two eligible patients will be randomly divided into 4 groups. Subjects will be randomized at a 1:1 ratio to receive either minodronate (1 mg/day) or alendronate (10 mg/day) every day, senior women (≥75 years old) and older women (<75 years old) will be at a ratio of 1:2. The primary outcome is the time required for the Visual Analogue Scale (VAS) score to decline by ≥10 from baseline, and the secondary outcome is the changes in VAS scores from baseline at 1, 2, 4, 6, 8, 12 and 24 weeks after administration and the frequency and dosage of rescue medication,pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of minodronate and alendronate in Chinese postmenopausal OP patients of different ages, and variations in upper gastrointestinal (GI) symptom scores from baseline (including heartburn, pain, and bloating).Results and discussion:This study will provide objective evidence for the efficiency and safety of minodronate in the treatment of postmenopausal OP with low back pain. Furthermore, it will be helpful to evaluate the quantitative relationship between bone turnover markers (BTM) and bone mineral density (BMD) in patients with OP underdifferent ages.Trial registration:This study protocol has been registered with ClinicalTrials.gov ID NCT05645289 on December 8th, 2022. The registry name is Peking University Third Hospital. This study protocol was reviewed and approved by the Peking University Third Hospital Medical Science Research Ethics Committee (M2022465, 2022.08.09, V2.0). The results will be published in scientific peer-reviewed journals.Trial status:Not yet recruiting. Recruitment is expected to begin in January 2023 and is expected to be completed in June 2024.

Publisher

Research Square Platform LLC

Reference38 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3